697 related articles for article (PubMed ID: 29266472)
1. Current treatment strategies for advanced prostate cancer.
Komura K; Sweeney CJ; Inamoto T; Ibuki N; Azuma H; Kantoff PW
Int J Urol; 2018 Mar; 25(3):220-231. PubMed ID: 29266472
[TBL] [Abstract][Full Text] [Related]
2. Treating Patients with Metastatic Castration Resistant Prostate Cancer: A Comprehensive Review of Available Therapies.
Crawford ED; Higano CS; Shore ND; Hussain M; Petrylak DP
J Urol; 2015 Dec; 194(6):1537-47. PubMed ID: 26196735
[TBL] [Abstract][Full Text] [Related]
3. EAU guidelines on prostate cancer. Part II: Treatment of advanced, relapsing, and castration-resistant prostate cancer.
Heidenreich A; Bastian PJ; Bellmunt J; Bolla M; Joniau S; van der Kwast T; Mason M; Matveev V; Wiegel T; Zattoni F; Mottet N;
Eur Urol; 2014 Feb; 65(2):467-79. PubMed ID: 24321502
[TBL] [Abstract][Full Text] [Related]
4. [Castration resistant prostate cancer 2015].
Merseburger AS; Böker A; Kuczyk MA; von Klot CA
Aktuelle Urol; 2015 Jan; 46(1):59-65. PubMed ID: 25658232
[TBL] [Abstract][Full Text] [Related]
5. EAU-ESTRO-SIOG Guidelines on Prostate Cancer. Part II: Treatment of Relapsing, Metastatic, and Castration-Resistant Prostate Cancer.
Cornford P; Bellmunt J; Bolla M; Briers E; De Santis M; Gross T; Henry AM; Joniau S; Lam TB; Mason MD; van der Poel HG; van der Kwast TH; Rouvière O; Wiegel T; Mottet N
Eur Urol; 2017 Apr; 71(4):630-642. PubMed ID: 27591931
[TBL] [Abstract][Full Text] [Related]
6. Therapeutic options for first-line metastatic castration-resistant prostate cancer: Suggestions for clinical practise in the CHAARTED and LATITUDE era.
Tucci M; Caffo O; Buttigliero C; Cavaliere C; D'aniello C; Di Maio M; Kinspergher S; Maines F; Rizzo M; Rossetti S; Veccia A; Scagliotti GV; Facchini G
Cancer Treat Rev; 2019 Mar; 74():35-42. PubMed ID: 30738364
[TBL] [Abstract][Full Text] [Related]
7. Current management of advanced and castration resistant prostate cancer.
Gomella LG; Petrylak DP; Shayegan B
Can J Urol; 2014 Apr; 21(2 Supp 1):1-6. PubMed ID: 24775717
[TBL] [Abstract][Full Text] [Related]
8. Treatment of Metastatic, Castration-resistant, Docetaxel-resistant Prostate Cancer: A Systematic Review of Literature With a Network Meta-analysis of Randomized Clinical Trials.
Tassinari D; Cherubini C; Roudnas B; Tamburini E; Drudi F; Bianchi E; Fantini M; Montanari F; Sartori S
Rev Recent Clin Trials; 2018; 13(3):226-237. PubMed ID: 29623850
[TBL] [Abstract][Full Text] [Related]
9. Metastatic castration-resistant prostate cancer. Part 1: the challenges of the disease and its treatment.
Bahl A
Eur J Oncol Nurs; 2013 Sep; 17 Suppl 1():S1-6. PubMed ID: 24461207
[TBL] [Abstract][Full Text] [Related]
10. Update on Systemic Prostate Cancer Therapies: Management of Metastatic Castration-resistant Prostate Cancer in the Era of Precision Oncology.
Nuhn P; De Bono JS; Fizazi K; Freedland SJ; Grilli M; Kantoff PW; Sonpavde G; Sternberg CN; Yegnasubramanian S; Antonarakis ES
Eur Urol; 2019 Jan; 75(1):88-99. PubMed ID: 29673712
[TBL] [Abstract][Full Text] [Related]
11. Treatment strategies in low-volume metastatic castration-resistant prostate cancer.
Wei XX; Ko EC; Ryan CJ
Curr Opin Urol; 2017 Nov; 27(6):596-603. PubMed ID: 28786849
[TBL] [Abstract][Full Text] [Related]
12. Sequencing of agents in castration-resistant prostate cancer.
Lorente D; Mateo J; Perez-Lopez R; de Bono JS; Attard G
Lancet Oncol; 2015 Jun; 16(6):e279-92. PubMed ID: 26065613
[TBL] [Abstract][Full Text] [Related]
13. Sipuleucel-T for the treatment of prostate cancer: novel insights and future directions.
Handy CE; Antonarakis ES
Future Oncol; 2018 Apr; 14(10):907-917. PubMed ID: 29260582
[TBL] [Abstract][Full Text] [Related]
14. New treatment options for patients with metastatic prostate cancer.
Snoeks LL; Ogilvie AC; van Haarst EP; Siegert CE
Neth J Med; 2013; 71(6):290-4. PubMed ID: 23956309
[TBL] [Abstract][Full Text] [Related]
15. Challenges in the sequencing of therapies for the management of metastatic castration-resistant prostate cancer.
Parente P; Parnis F; Gurney H
Asia Pac J Clin Oncol; 2014 Sep; 10(3):205-15. PubMed ID: 24750803
[TBL] [Abstract][Full Text] [Related]
16. Radium-223 and concomitant therapies in patients with metastatic castration-resistant prostate cancer: an international, early access, open-label, single-arm phase 3b trial.
Saad F; Carles J; Gillessen S; Heidenreich A; Heinrich D; Gratt J; Lévy J; Miller K; Nilsson S; Petrenciuc O; Tucci M; Wirth M; Federhofer J; O'Sullivan JM;
Lancet Oncol; 2016 Sep; 17(9):1306-16. PubMed ID: 27473888
[TBL] [Abstract][Full Text] [Related]
17. Combination radium-223 therapies in patients with bone metastases from castration-resistant prostate cancer: A review.
Cursano MC; Iuliani M; Casadei C; Stellato M; Tonini G; Paganelli G; Santini D; De Giorgi U
Crit Rev Oncol Hematol; 2020 Feb; 146():102864. PubMed ID: 31986318
[TBL] [Abstract][Full Text] [Related]
18. A real-world evaluation of radium-223 in combination with abiraterone or enzalutamide for the treatment of metastatic castration-resistant prostate cancer.
Kim SI; Szeto AH; Morgan KP; Brower B; Dunn MW; Khandani AH; Godley PA; Rose TL; Basch EM; Milowsky MI; Whang YE; Crona DJ
PLoS One; 2021; 16(6):e0253021. PubMed ID: 34153052
[TBL] [Abstract][Full Text] [Related]
19. The role of sipuleucel-T in therapy for castration-resistant prostate cancer: a critical analysis of the literature.
Sonpavde G; Di Lorenzo G; Higano CS; Kantoff PW; Madan R; Shore ND
Eur Urol; 2012 Apr; 61(4):639-47. PubMed ID: 22036643
[TBL] [Abstract][Full Text] [Related]
20. Prediction of PSA Progression in Castration-Resistant Prostate Cancer Based on Treatment-Associated Change in Tumor Burden Quantified by 18F-Fluorocholine PET/CT.
Lee J; Sato MM; Coel MN; Lee KH; Kwee SA
J Nucl Med; 2016 Jul; 57(7):1058-64. PubMed ID: 26912444
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]